Neuropeptide Y (NPY) Suppresses Experimental Autoimmune Encephalomyelitis: NPY1 Receptor-Specific Inhibition of Autoreactive Th1 Responses In Vivo
Sammy Bedoui(The University of Melbourne), Takashi Yamamura(National Center of Neurology and Psychiatry), Stephan von Hörsten(Friedrich-Alexander-Universität Erlangen-Nürnberg), Annette G. Beck‐Sickinger(Leipzig University), Katsuichi Miyamoto(Hiroshima University), Youwei Lin(National Center of Neurology and Psychiatry), Noriyuki Kawamura(National Center of Neurology and Psychiatry), Shinji Oki(National Center of Neurology and Psychiatry), Sachiko Miyake(Juntendo University)
Cited by 100
Related Papers
XVI. International Union of Pharmacology Recommendations for the Nomenclature of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Receptors
|Pharmacological Reviews|1998|893
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
|The Lancet Neurology|2020|495
GPR39 Signaling Is Stimulated by Zinc Ions But Not by Obestatin
|Endocrinology|2006|432
Herbal drugs and phytopharmaceuticals
|Pharmaceutica Acta Helvetiae|1995|415
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390